Grace Therapeutics — Second Quarter 2027 Earnings Summary

Grace Therapeutics reported a net loss of $2.1 million for the three months ended September 30, 2026, driven by increased research and development expenses related to its dual-source manufacturing strategy for GTx-104. The company completed a $10 million private placement in August 2026, extending its cash runway through the end of 2028 to support regulatory resubmission efforts for its New Drug Application. Following a Complete Response Letter from the FDA in April 2026, Grace Therapeutics is addressing chemistry, manufacturing, and controls issues while initiating technology transfer to a second U.S.-based contract manufacturer. As of September 30, 2026, the company held $21.3 million in cash and cash equivalents to fund operations and resolve FDA-identified items.